Objective: To examine the possible reasons for great varieties in urethral prostate specific antigen (urPSA) levels, in patients after radical prostatectomy (RP). Materials and methods: In 46 patients with pros-tate cancer, PSA, urPSA, total testosterone, body-mass index (BMI) and the stage of androgenic alopecia (AGA) were determined. Forty-five patients underwent retropubic RP, while one underwent cystoprostatectomy with orthotopic bladder construction, due to bladder cancer. Results: Average patients age prior to surgery plus or minus standard deviation was 65.2+5.8 years. Average urPSA was 20.9+47.5 ng/ml (0.05 to 212 ng/ml, median 2.24 ng/ml). With urethral PSA cut-off of 2.0 ng/ml, two groups were formed: A (urPSA < 2.0 ng/ml) and B (urPSA = 2.0 ng/ml). Patients in the group A had significantly lo-wer average AGA score, than the patients from the group B (2.4+1.3 vs. 4.4+2.2, p=0.0003). In addition, patients from the group A had significantly lower pos-toperative PSA (0.07+0.08 ng/ml vs. 0.14 + 0.06 ng/ml, p=0.0014). Conclusions: The patients with higher urPSA have higher AGA scores and higher postoperative PSA. This phenomenon is probably the consequence of higher local dihydrotestosterone activity in the scalp and PSA-secreting urethral glands.
INTRODUCTION
A fter successful radical prostatectomy, serum levels of prostate specific antigen (PSA) are usually very low. However, the acceptable PSA values among various patients may differ significantly, from 0.001 or less, to 0.2ng/ml 1 . Today, it is not quite clear where the source of PSA in the patients without relapse is. The possible sources of PSA are urethral epithelial cells and foci of cystitis cystica/ glandularis 2 but there is still no consensus about that 3 . There is a great variety in urethral PSA production; these values may differ more than thousand times in the first urinary stream, from 0.1 to 100 ng/ml 4 . As the urethral PSA production is under androgen control 5 , these differences could be the consequence of different androgen activity in urethral epithelial cells, rather than the different penile or urethral size. Dihydrotestosterone (DHT) is the most important intracellular androgen and the main regulator of PSA expression in prostatic epithelial cells 6 . As urethral PSA-secreting cells are morphologically identical to prostatic epithelial cells 2 , DHT is most probably the main androgen that influences urethral PSA production. Increased intracellular DHT activity is responsible for the development of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA) in men; frequently, both conditions could be found in one patient 7 .
ANDROGENS AND BALDNESS
The most important androgens in males are testosterone, which mediates masculinization in the adult, and DHT, which mediates prostatic growth, acne, facial beard, and male pattern baldness 8 . Embryological development of both the hair follicle and the prostate depends on mesenchymal-epithelial interaction, which is influenced by the expression of 5-alpha reductase 9 . Male pattern hair loss, or AGA, is the consequence of the progressive miniaturization of scalp hair. Observations in both eunuchs, who have low levels of testicular androgens, and males with low DHT due to genetic 5-alpha reductase deficiency, implicate DHT as a key androgen in the pathogenesis of AGA
10
.
ANDROGENS AND PSA SYNTHESIS
The synthesis of PSA, the most important prostatic enzyme, is also DHT-dependent. After entering the epithelial cell, androgens react with 5-alpha reductase, which converts them into more potent hormone, DHT. After the synthesis, PSA molecules are contained in prostatic secretory granules, which discharge their content out from the cell. Following that, PSA molecules leak through prostatic ducts to the prostatic urethra, where they collect, until the next micturition or ejaculation happens.
URETHRAL PSA SECRETION
Additional PSA molecules are secreted diffusely, along entire urethra, from so-called minor prostatic glands. All minor prostatic glands are made of prostatic glands, or of prostatic and mucinous epithelium. It seems that minor prostatic glands represent evolutionary remnant. Namely, early mammals, that appeared 65 million years ago, probably had primitive prostate consisted of disseminated prostatic glands in the urethra, socalled disseminated prostate 12 . In the present time, small, microscopic disseminated prostates can be seen in whales and dolphins, and larger one in other mammals, like boar, ram and bull; the mammals on the higher evolutionary position, including primates, developed compact organ [13] [14] [15] . In primates and humans, these glands probably provide diffuse presence of PSA in the urethra and, maybe, take place in the cleansing of the urethra after the ejaculation. All PSA molecules detected in the urine, were washed-out from the urethra during the micturition. Namely, 32.9 kDa heavy PSA molecule, cannot pass the glomerular membrane; it is proved that no PSA can be detected in the urine from ileal conduits, or nephrostomy catheters 16, 17 .
MATERIALS AND METHODS

The patients
This prospective-retrospective study enclosed 46 patients with prostate cancer without evidence of recurrent disease after surgery. Forty-five patients underwent radical retropubic prostatectomy, while one patient underwent cystoprostatectomy with orthotopic bladder construction, due to bladder cancer. All patients underwent surgery from June 2000. to June 2008, in the Urological Clinic, Clinical Center of Serbia, Belgrade, by single urologist (T.P). The average age prior to surgery plus or minus standard deviation (SD) was 65.2+5.8 years (range 52 to 76 years), with the average follow-up of 41.7+24.9 months (12 to110 months). Current average age +SD was 67+6.6 years (range 53 to 82 years). There were no patients receiving additional therapy and all patients were free of urinary infection in the time of collecting urine specimen. The majority of patients collected multiple urPSA samples every three or six months; and average urPSA value was calculated.
THE DETERMINATION OF PSA IN THE URINE
All patients collected first 75ml (full urine-sample container) of the first morning urine at home and it was standard urine volume for the determination of PSA. All biochemical tests and measurement were done in the laboratory of Urological clinic, Clinical Centre of Serbia, Belgrade. For both serum and urinary PSA determination, Axsym PSA assay (Abbott Laboratories, Illinois, USA) was used. Total serum testosterone was determined postoperatively, using MEIA Abbott-Axsym assay. The methodology for processing PSA in the urine was described by Takayama in 1994. 18 The urine was titrated with NaOH until the pH of 7.5 was reached. Urine samples were spun in the centrifuge at 2000 rpm for 10 minutes. Aliquots of 500 µl samples were frozen at -20C and stored. Urine samples were thawed only ones prior to determination of PSA.
HAMILTON-NORWOOD SCALE OF BALDNESS
The assessment of the hair pattern and the grade of the androgenic alopecia (AGA) was done by competent urologist, using the illustration of the Hamilton-Norwood Scale of Baldness 
THE STATISTICS
Statistical differences were calculated using Student's ttest for independent samples.
RESULTS
There were 36 patients with pT2N0 stage and 10 patients with pT3N0 stage. Average urethral PSA, plus or minus standard deviation (SD), was 20.9+47.5 ng/ml (range 0.05 to 212 ng/ml, median 2.24 ng/ml). Average preoperative PSA was 8+4.3 ng/ml (range 1.2 to 24.3 ng/ml, median 7.2 ng/ml). The lowest PSA value belonged to the patient with bladder cancer. Average postoperative PSA + SD was 0.11+0.08 ng/ml (range 0.002 to 0.25 ng/ml, median 0.095 ng/ml). Average total testosterone + SD was 15.2+6.6 nmol/L (range 6.1-27.4 nmol/L). Average prostate volume was 42.2+23.8 ml.
With urethral PSA cut-off of 2.0 ng/ml, two groups were formed: A (urPSA < 2.0 ng/ml) and B (urPSA = 2.0 ng/ml). Patients in the group A had significantly lower average AGA score, than the patients from the group B (2.4+1.3 vs. 4.4+2.2, p=0.0003).
In addition, patients from the group A had significantly lower postoperative PSA (0.07+0.08 ng/ml vs. 0.14+0.06 ng/ml, p=0.0014). (Table 1. ).
However, there were no differences in current age, BMI, and total testosterone level.
Likewise, there were no differences in preoperative PSA and prostate volume.
There were no differences in definitive tumor stage, tumor grade and Gleason score between the groups.
DISCUSSION
The development of the normal prostate, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are under genetic and hormonal influences. Likewise, male pattern hair loss is the consequence of genetic predis-position and local androgenic metabolism 21 . It seems that bald men have higher serum DHT, but similar serum testosterone, compared to men with normal hair pattern. However, some authors found higher levels of free testosterone in men with vertex baldness, which can be considered as possible risk factor for PCa development. At last, some authors found higher prevalence of AGA in the patients with larger prostates, as common consequence of increased local DHT activity in the scalp and prostatic epithelial cells. Finasteride, 5-alpha reductase (5-ARI) type II inhibitor and dutasteride, dual 5-ARI, markedly decrease serum and intraprostatic DHT concentrations, as well as DHT concentration in the hair follicle [22] [23] [24] [25] [26] . As both genetic and hormonal factors play an important role in the development of all human organs, baldness could serve as a good surrogate marker for genetic and local DHT influences.
Despite the fact that PSA concentration is higher in the urine than in the blood, uPSA determination has never been routinely used in the clinical practice. Nevertheless, the fact that urinary PSA levels strongly depend on androgen level and follow the changes in androgen concentrations is well known. In the first scientific issues, high concentrations of PSA were found in the urine of patients with BPH, and low concentrations in the urine of patients after RP. However, while some authors found significant differences in serum-to-urinary PSA ratio in patients with BPH and PCa, the others did not [27] [28] [29] [30] . Later studies proved that uPSA in patients that underwent RP, originates from periurethral glands. The synthesis and production of PSA was detected even in female urethral glands, after testosterone administration in female-to-male transsexuals 31, 32 . Increased local DHT production is probably the common cause of increased PSA synthesis, prostatic epithelial cells growth and AGA. However, urethral minor prostatic glands represent better model for the evaluation of DHT influence on PSA production, than the whole prostate gland. Namely, urethral PSA production can be clearly measured in the urine, while many factors complicate the assessment of PSA production in the prostate gland. The examination of isolated urethral PSA pro-duction is possible only in the absence of the prostate, i.e. after RP. In this issue, men after radical prostatectomy, without evidence for recurrent disease, had urethral PSA values from 0.05 to 212 ng/ml, median 2.24 ng/ml. (The patient with highest urPSA had constantly high urPSA levels from January 2007 and low PSA, measuring 0.1ng/ml; his BMI was 24.1 and his body hair distribution and penile length usual).
The patients with urPSA = 2.0 ng/ml had higher AGA score and higher postoperative PSA than the patients with urPSA < 2.0 ng/ml and that were the only differences between these two groups. There were no di-fference in average age, BMI, preoperative prostate vo-lume, tumor grade and stage between the groups. It seems that the difference emerged due to higher local DHT ac-tivity in target tissues, i.e. in the PSA-secreting urethral glands and the scalp. Although it was expected that the patients with higher urPSA had larger prostates before surgery, it was not proved.
The intriguing fact is that patients with higher urPSA had higher postoperative PSA, but there were no correlation between urPSA and postoperative PSA level. However, there is a possibility that urethral PSA production takes part in the total serum PSA concentration after radical prostatectomy. Indeed, in the group with urPSA = 2.0 ng/ml, there were three patients with urPSA over 100 ng/ml, which is comparable with prostatic PSA production. In the previous report, in the group of patients with BPH, the authors found urinary PSA levels ranged from 28.7 to 445 ng/ml, median 206.8 ng/ml [33] . However, this hypothesis has to be proved in further investigations.
REZIME KOJI SU MOGU]I RAZLOZI VELIKIH VARIJACIJA PSA POSLE RADIKALNE PROSTATEKTOMIJE
Cilj rada: Ispitati koji su mogu}i uzroci velikih varijacija vrednosti uretralnog prostata specifi~nog antigena (urPSA), izmedju razli~itih bolesnika kod kojih je u~in-jena radikalna retropubi~na prostatektomija (RRP).
Materijal i metode: Kod 46 bolesnika sa lokalizovanim karcinomom prostate odredjivani su PSA, urPSA, ukupni testosteron, indeks telesne mase (body-mass index, BMI), kao i stadijum androgene alopecije (AGA). Kod 45 bolesnika je u~injena RRP, a kod jednog bolesnika je u~injena cistoprostatektomija sa konstrukcijom ortotopske bešike, zbog infiltrativnog tumora bešike.
Rezultati: Prose~na starost bolesnika pre operacije ( plus/minus standardna devijacija, SD), bila je 65.2+5.8 godina. Prose~na vrednost urPSA je bila 20.9+47.5 ng/ml (opseg 0.05 do 212 ng/ml, mediana 2.24 ng/ml). Kada se za grani~nu vrednost urPSA uzme vrednost od 2.0 ng/ml, mogu da se formiraju dve grupe: A, sa urPSA < 2.0 ng/ml i B, sa urPSA = 2.0 ng/ml. Bolesnici u grupi A su imali zna~ajno ni'i skor AGA, nego bolesnici u grupi B (2.4+ 1.3 prema 4.4+2.2, p=0.0003). Osim toga, bolesnici u grupi A su imali zna~ajno ni'i postoperativni PSA (0.07 +0.08 ng/ml prema 0.14+0.06 ng/ml, p=0.0014).
Zaklju~ak: Posle RRP, bolesnici sa višim urPSA imaju viši stepen AGA i viši postoperativni PSA. Ovaj fenomen je verovatno posledica ve}e lokalne aktivnosti dihidrotestosterona u ko'i glave i u uretralnim 'lezdama koje proizvode PSA.
Klju~ne re~i: androgena alopecija, prostata specifi~ni antigen, radikalna prostatektomija, uretralne 'lezde, uretralni PSA, urinarni PSA.
